George A. Scangos Sells 10,964 Shares of Vir Biotechnology, Inc. (NASDAQ:VIR) Stock

Vir Biotechnology, Inc. (NASDAQ:VIR) Director George A. Scangos sold 10,964 shares of the firm’s stock in a transaction dated Tuesday, February 18th. The shares were sold at an average price of $9.81, for a total transaction of $107,556.84. Following the completion of the transaction, the director now directly owns 708,295 shares in the company, valued at approximately $6,948,373.95. The trade was a 1.52 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website.

Vir Biotechnology Trading Up 1.7 %

NASDAQ VIR opened at $9.85 on Thursday. The business’s fifty day moving average is $9.22 and its 200-day moving average is $8.47. Vir Biotechnology, Inc. has a one year low of $6.56 and a one year high of $14.45.

Wall Street Analyst Weigh In

A number of research firms have recently weighed in on VIR. Needham & Company LLC restated a “buy” rating and issued a $19.00 target price on shares of Vir Biotechnology in a report on Wednesday, November 20th. HC Wainwright restated a “buy” rating and set a $110.00 price objective on shares of Vir Biotechnology in a research note on Friday, January 31st. JPMorgan Chase & Co. lifted their price objective on shares of Vir Biotechnology from $10.00 to $14.00 and gave the stock a “neutral” rating in a report on Thursday, January 9th. Morgan Stanley upgraded shares of Vir Biotechnology from an “equal weight” rating to an “overweight” rating and increased their target price for the company from $10.00 to $20.00 in a report on Thursday, January 9th. Finally, Barclays cut their price target on shares of Vir Biotechnology from $28.00 to $26.00 and set an “overweight” rating on the stock in a report on Monday, November 4th. One analyst has rated the stock with a hold rating and five have issued a buy rating to the stock. According to data from MarketBeat.com, Vir Biotechnology currently has a consensus rating of “Moderate Buy” and a consensus target price of $34.83.

Institutional Trading of Vir Biotechnology

Several hedge funds have recently added to or reduced their stakes in VIR. State Street Corp raised its stake in shares of Vir Biotechnology by 10.4% in the third quarter. State Street Corp now owns 5,625,533 shares of the company’s stock valued at $42,135,000 after buying an additional 530,645 shares during the period. Geode Capital Management LLC increased its holdings in Vir Biotechnology by 0.4% in the 4th quarter. Geode Capital Management LLC now owns 2,196,601 shares of the company’s stock worth $16,127,000 after acquiring an additional 7,827 shares during the last quarter. Dimensional Fund Advisors LP raised its stake in Vir Biotechnology by 58.0% in the 4th quarter. Dimensional Fund Advisors LP now owns 1,915,465 shares of the company’s stock valued at $14,059,000 after acquiring an additional 703,360 shares during the period. Millennium Management LLC lifted its holdings in Vir Biotechnology by 55.3% during the fourth quarter. Millennium Management LLC now owns 1,715,083 shares of the company’s stock valued at $12,589,000 after purchasing an additional 610,367 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. boosted its position in Vir Biotechnology by 10.4% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 1,252,655 shares of the company’s stock worth $9,194,000 after purchasing an additional 118,379 shares during the period. Institutional investors own 65.32% of the company’s stock.

Vir Biotechnology Company Profile

Vir Biotechnology, Inc, an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company’s preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV).